Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease

The gut microbiota can impact the bioavailability of therapeutic drugs. Here, the authors show that bacterial tyrosine decarboxylases (TDC) decrease the levels of levodopa, the primary treatment in Parkinson’s disease, by conversion to dopamine, and suggest TDC as a potential predictive biomarker fo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sebastiaan P. van Kessel, Alexandra K. Frye, Ahmed O. El-Gendy, Maria Castejon, Ali Keshavarzian, Gertjan van Dijk, Sahar El Aidy
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2019
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/b417af8f89cb4dab815828a72e3ff5dd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b417af8f89cb4dab815828a72e3ff5dd
record_format	dspace
spelling	oai:doaj.org-article:b417af8f89cb4dab815828a72e3ff5dd2021-12-02T16:57:32ZGut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease10.1038/s41467-019-08294-y2041-1723https://doaj.org/article/b417af8f89cb4dab815828a72e3ff5dd2019-01-01T00:00:00Zhttps://doi.org/10.1038/s41467-019-08294-yhttps://doaj.org/toc/2041-1723The gut microbiota can impact the bioavailability of therapeutic drugs. Here, the authors show that bacterial tyrosine decarboxylases (TDC) decrease the levels of levodopa, the primary treatment in Parkinson’s disease, by conversion to dopamine, and suggest TDC as a potential predictive biomarker for treatment.Sebastiaan P. van KesselAlexandra K. FryeAhmed O. El-GendyMaria CastejonAli KeshavarzianGertjan van DijkSahar El AidyNature PortfolioarticleScienceQENNature Communications, Vol 10, Iss 1, Pp 1-11 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Sebastiaan P. van Kessel Alexandra K. Frye Ahmed O. El-Gendy Maria Castejon Ali Keshavarzian Gertjan van Dijk Sahar El Aidy Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease
description	The gut microbiota can impact the bioavailability of therapeutic drugs. Here, the authors show that bacterial tyrosine decarboxylases (TDC) decrease the levels of levodopa, the primary treatment in Parkinson’s disease, by conversion to dopamine, and suggest TDC as a potential predictive biomarker for treatment.
format	article
author	Sebastiaan P. van Kessel Alexandra K. Frye Ahmed O. El-Gendy Maria Castejon Ali Keshavarzian Gertjan van Dijk Sahar El Aidy
author_facet	Sebastiaan P. van Kessel Alexandra K. Frye Ahmed O. El-Gendy Maria Castejon Ali Keshavarzian Gertjan van Dijk Sahar El Aidy
author_sort	Sebastiaan P. van Kessel
title	Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease
title_short	Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease
title_full	Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease
title_fullStr	Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease
title_full_unstemmed	Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease
title_sort	gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of parkinson’s disease
publisher	Nature Portfolio
publishDate	2019
url	https://doaj.org/article/b417af8f89cb4dab815828a72e3ff5dd
work_keys_str_mv	AT sebastiaanpvankessel gutbacterialtyrosinedecarboxylasesrestrictlevelsoflevodopainthetreatmentofparkinsonsdisease AT alexandrakfrye gutbacterialtyrosinedecarboxylasesrestrictlevelsoflevodopainthetreatmentofparkinsonsdisease AT ahmedoelgendy gutbacterialtyrosinedecarboxylasesrestrictlevelsoflevodopainthetreatmentofparkinsonsdisease AT mariacastejon gutbacterialtyrosinedecarboxylasesrestrictlevelsoflevodopainthetreatmentofparkinsonsdisease AT alikeshavarzian gutbacterialtyrosinedecarboxylasesrestrictlevelsoflevodopainthetreatmentofparkinsonsdisease AT gertjanvandijk gutbacterialtyrosinedecarboxylasesrestrictlevelsoflevodopainthetreatmentofparkinsonsdisease AT saharelaidy gutbacterialtyrosinedecarboxylasesrestrictlevelsoflevodopainthetreatmentofparkinsonsdisease
_version_	1718382525191028736

Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease

Ejemplares similares